CSI Market
Sign In | Register

Innate Pharma Sa (IPHA) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access IPHA Annual Cash Flow →
By examining cash flow figures across successive periods, users can identify shifts in Innate Pharma Sa's cash generation and deployment strategy.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		0 0 0 (Dec 31 2024)
Operating Activities
Income-55.08
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Adjustments For Gain Loss On Disposals PropertyPlant And Equipment0.03
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction1.02
Adjustments For Depreciation And Amortisation Expense-
Adjustments For Increase Decrease In Employee Benefit Liabilities-
Adjustments For Provisions-
Adjustments For Sharebased Payments-
Adjustments For Unrealised Foreign Exchange Losses Gains-
Adjustments For Decrease Increase In Accrued Interests On Financial Assets-
Change In Accrued Interests On Financial Assets-
Adjustments For Finance Income-
Adjustments For Finance Costs-
Cash Flows From Used In Operations Before Changes In Working Capital-
Increase Decrease In Working Capital-
Income taxes0.00
Purchase Of Intangible Assets Classified As Investing Activities0.00
Accounts Receivable0.00
Accounts Payable0.00
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Other Adjustments To Reconcile Profit Loss0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities46.78
Discontinued operations0.00
Net Cash flow from Operating Activities-59.09
Investing Activities
Capital Expenditures-0.16
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Proceeds From Other Longterm Assets Classified As Investing Activities-
Purchase Of Other Longterm Assets Classified As Investing Activities-
Disposal Of Current Financial Instruments-
Disposal Of Non Current Financial Instruments-
Interest Received Classified As Investing Activities-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Purchase Of Financial Instruments Classified As Investing Activities0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net7.88
Discontinued operations0.00
Net Cash Flow from Investing Activities8.16
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net49.70
Increase Decrease In Cash And Cash Equivalents-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities6.80
Effect of exchange rate on cash flow1.22
Discontinued operations0.00
Free Cash Flow-59.24
Total Cash Flow74.36
4 historic quarters locked

Sign in to unlock the full Innate Pharma Sa cash flow history.

Sign In Create Free Account

About Innate Pharma Sa Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 20-F filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001598599-26-000005

Figures are derived from filed reports and may be restated. Historical data is subject to revision.